STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
STAT
FEBRUARY 5, 2024
But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug Wegovy, plans to buy Catalent , a company to which drugmakers outsource manufacturing, is probably even more important than it seems. Sixteen billion dollars is a lot of money. Continue to STAT+ to read the full story…
Let's personalize your content